TidalSense
TidalSense is a venture-backed respiratory technology company founded in 2013, headquartered in Cambridge, UK. The company is dedicated to revolutionizing respiratory care through AI-driven diagnostic and monitoring technologies. Their flagship product, N-Tidal™ Diagnose, is a CE-marked Class 2a medical device under EU MDR for COPD diagnosis, offering rapid, accurate, point-of-care assessment. N-Tidal™ Capture provides remote patient monitoring using their proprietary digital biomarkers. The technology is built on a patented sensor, developed over 10 years, which captures breath data for analysis by an AI-powered cloud platform. TidalSense aims to improve population-level outcomes for respiratory patients by enabling earlier intervention and personalized treatment.
TidalSense
TidalSense is a venture-backed respiratory technology company founded in 2013, headquartered in Cambridge, UK. The company is dedicated to revolutionizing respiratory care through AI-driven diagnostic and monitoring technologies. Their flagship product, N-Tidal™ Diagnose, is a CE-marked Class 2a medical device under EU MDR for COPD diagnosis, offering rapid, accurate, point-of-care assessment. N-Tidal™ Capture provides remote patient monitoring using their proprietary digital biomarkers. The technology is built on a patented sensor, developed over 10 years, which captures breath data for analysis by an AI-powered cloud platform. TidalSense aims to improve population-level outcomes for respiratory patients by enabling earlier intervention and personalized treatment.
TL;DR
Founded: 2013
Headquarters: Cambridge, UK
Product: N-Tidal (Diagnose & Capture) — CE-marked Class 2a device for COPD diagnosis
Tech: Patented CO2 sensor + AI cloud platform
Recent funding: Seed round May 2023 (~£7.5M) led by BGF & Downing Ventures
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Respiratory diagnostics and remote patient monitoring for obstructive lung disease (e.g., COPD, asthma).
Founded
2013
Industry
Software Development
Tech Stack
Funding Track Record
£7.5 million
Reported May 16, 2023 round; company cites ~£13M in financial support to date from investors and funders including BGF, Downing, Foresight Group, Innovate UK, SBRI Healthcare, NIHR and Asthma + Lung UK.
Investor Signal
“Backed by institutional investors including Business Growth Fund (BGF), Downing Ventures and Foresight Group; has received grant and public fund support (e.g., Innovate UK, SBRI Healthcare, NIHR).”